.Nature Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free and total survival, bring about FDA approval and a new procedure option for clients.